GV.PA Genomic Vision (EURONEXT) 20 Feb 2026 Market Closed: €0.0018, heavy volume

GV.PA stock closed the market on 20 Feb 2026 at €0.0018, up 5.88% on heavy turnover. The most-active tag reflected 38,489,238 shares traded on EURONEXT in Europe, nearly three times average volume. Short-term moves track liquidity and low free float rather than fresh fundamentals. We review intraday drivers, financial metrics, Meyka AI grade and a short-term price roadmap for traders and investors.

GV.PA stock performance and intraday drivers

Genomic Vision SA (GV.PA) finished the session at €0.0018 with a day range of €0.0015–€0.0020. Volume reached 38,489,238 versus an average of 14,217,513, producing a relative volume of about 2.71. The spike in trades makes GV.PA one of the most active small-caps on EURONEXT today. Price action appears driven by speculative trading and liquidity events, not a material operational update.

Financials, valuation and sector context for GV.PA stock

Genomic Vision operates in Healthcare, Medical – Diagnostics & Research, with trailing EPS -0.11 and a negative PE. Market cap stands near €693,191 with 385,105,984 shares outstanding. Price-to-sales is 0.47 and EV/sales is 1.60, but book value per share is negative. Healthcare peers show modest YTD movement; the sector YTD is -0.98%, so GV.PA lags on fundamentals and scale.

Liquidity, technicals and trading risks for GV.PA stock

Liquidity can magnify small orders into sharp percentage moves. GV.PA’s 50-day average €0.00484 and 200-day average €0.013997 sit well above today’s price, highlighting steep downtrend over months. Bid-ask spreads and low market cap raise execution risk. Short-term technicals show a gap between intraday high €0.0020 and the 50-day average, which traders should treat as resistance.

Meyka AI grade and model forecast for GV.PA stock

Meyka AI rates GV.PA with a score out of 100: 62.44 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 12-month reference target of €0.0060 versus the current €0.0018, implying an estimated upside of 233.33%. Forecasts are model-based projections and not guarantees.

Catalysts, partnerships and risks that move GV.PA stock

Genomic Vision lists partnerships with Quest Diagnostics and research ties with Institut Pasteur. Commercial traction for FiberVision products would be a positive catalyst. Key risks are persistent negative margins, stretched cash conversion cycles, and high debt-to-market-cap metrics. Regulatory, dilution from capital raises, or weak uptake could push price lower toward liquidity-driven support.

Trading outlook and price targets for GV.PA stock

For traders, expect volatile intraday swings and thin depth. Short-term levels: support €0.0010, immediate resistance €0.0025. Meyka AI’s mid-term projection is €0.0060, and a downside stress case sits near €0.0010. Position sizing and stop discipline are essential given GV.PA’s microcap profile. For news flow, watch clinical updates and any partnership announcements closely (source) and sector deal news (source).

Final Thoughts

GV.PA stock closed at €0.0018 on EURONEXT with outsized volume, confirming its status among the market’s most active names today. The company’s diagnostics tech and partnerships are constructive, but weak margins, negative equity per share and stretched cash metrics raise real risk for investors. Meyka AI rates GV.PA 62.44 (B, HOLD) and models a 12-month reference target of €0.0060, implying +233.33% upside from €0.0018. That scenario relies on improved sales or a successful capital strategy. Forecasts are model-based projections and not guarantees. Short-term traders may trade tight ranges between €0.0010 and €0.0025, while longer-term investors should wait for clearer revenue traction or balance sheet repair. Meyka AI, as an AI-powered market analysis platform, will monitor flow and fundamentals for updates.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.